SMAD3 and fibrosis: Inhibition of the TGF-β1/SMAD3 signaling pathway ameliorates non-alcoholic steatohepatitis, tubulointerstitial fibrosis, and myocardium infraction (Chen et al., 2019; He et al., 2020; Okina et al., 2020).